The present invention relates to processes for the crystallisation and for thepreparation and isolation of a novel crystalline form of fusidic acid, to theuse of said processes in the manufacture of pharmaceutical formulation ormedicament, and to the use of said crystalline fusidic acid form for thetreatment of bacterial infections.